The US Food and Drug Administration (FDA) has given 510(k) clearance to Neural Analytics to market its next generation ultrasound device, the Lucid M1 Transcranial Doppler Ultrasound System (Lucid System).

The Lucid System is a fully portable all-in-one ultrasound system for rapid triaging and monitoring of patients with brain disorders.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Neural Analytics CEO Leo Petrossian said: “Neural Analytics Lucid System is the first truly portable ultrasound system to assess brain blood flow, and is the first product we will commercialise in the US.

“This is a significant milestone for our organisation, and more importantly, represents a step forward in improving the care of all patients suffering from blood flow disorders.”

The Lucid System analyses the brain’s blood vessels from outside the body using a type of ultrasound called Trans Cranial Doppler.

See Also:

This non-invasive analysis can be performed in a physician’s office, thereby helping the diagnosis of brain disorders and eliminating the need of additional, invasive tests.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.
"The Lucid System offers the ability to accurately measure the flow of blood in the brain, which is critical to assess and monitor patients suspected of severe brain conditions."

The Lucid System has been developed as a battery operated medical grade tablet device which can be moved easily across a medical facility in a range of settings that require the rapid assessment of blood flow in the brain in order to accelerate treatment.

Neural Analytics chief medical officer Neil Martin said: “The Lucid System offers the ability to accurately measure the flow of blood in the brain, which is critical to assess and monitor patients suspected of severe brain conditions.

“Thanks to the portability of the product, for the first time, clinicians will be able to bring this level of care directly to the patient prior to the need for more complex and invasive tests.”

Image: The Lucid M1 Transcranial Doppler Ultrasound System. Photo: courtesy of Business Wire.